TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA-based therapeutics ...

MAPKeeper 301 is a global, randomized, open-label, multicenter Phase 3 clinical trial evaluating atebimetinib in combination with modified gemcitabine and nab-paclitaxel compared with standard ...

Global Phase 2b/3 Study Will Evaluate Symptom Duration and Hospitalization Rates in Adult Outpatients at High Risk of Severe Outcomes from RSV WATERTOWN, Mass. -- (BUSINESS WIRE)--Oct. 26, 2026-- ...

Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occ ...

Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with ...

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...

Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of ...

XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumorsAnticipate ...

For patients with desmoid tumors, treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome.

The most common treatment-emergent adverse events (TEAEs) (all grade/Grade 3-4) were asthenia (51%/7%), acneiform dermatitis (51%/7%), and rash (49%/2%). Infusion-related reactions occurred in 38% of ...

AstraZeneca's experimental antibody-drug conjugate sonesitatug vedotin has doubled overall survival in a late-stage trial for advanced stomach cancer patients, offering renewed hope for hard-to-treat ...

Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia - - SGT-212 is a ...